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This workshop, which attempted to define the
clinical trials which should be instituted to explore
the usefulness of retinoids in oncology, immediately
followed a 3-day CIBA symposium entitled
"Retinoids, differentiation and disease" which
concentrated on the mechanism of action of
retinoids. Highlights of the CIBA symposium were
presented by M. Hicks (London) who drew
attention to the new and exciting relationships
which are emerging between oncogenes, growth
factors and cellular responsiveness to retinoids.
There was no real consensus as to whether a single
mode of action at the molecular level will be
defined for all target cells, or even if all retinoids
operate by the same basic mechanisms. Another
point at issue was whether or not the cellular
retinoic acid and retinol-binding proteins constitute
true receptors essential for retinoid activity. The
new retinoidal benzoic acid derivatives (the
alternative name arotenoids should be avoided) are
1000 times more active than retinol in several test
systems but their therapeutic dose range is close to
their toxic range. Their value is expected to be as
an aid in identifying the receptor(s), isolating them
from the membrane and finally cloning the gene(s)
responsible.
Thousands of synthetic derivatives of Vitamin A
(retinoids) have now been produced and there
appears to be a great variation in the target
specifivity (and therefore effectiveness and toxicity)
between them. Various retinoids were shown at the
CIBA symposium to exert potent modulatory
effects on immune function, the pattern of
regenerating amphibian and avian limbs, chemical
carcinogenesis and rheumatoid arthritis. Following
the discussion on the various manifestations of
retinoid toxicity, most participants agreed that the
clinical requirements were not for more active
retinoids, but for less toxic analogues.
The chemopreventive role of retinoids in
carcinogen induced animal tumours was discussed
by R. Moon (Chicago). He demonstrated that the
delay in appearance of methylnitrosourea-induced
mammary carcinomas in rats was related to the
dose and particular retinoid administered. At a
non-toxic dose 4-hydroxyphenylretinamide (HPR)
induced the greatest growth delay. Several other
retinoids, including 13 cis retinoic acid and
etretinate, were ineffective in this model. HPR
administration could be delayed up to 16 weeks
and still have an inhibitory effect. When HPR was
combined with hormonal therapy an additive chemo-
preventive effect was found with Tamoxifen and a
synergistic effect was found with oophorectomy and
a prolactin inhibitor.
There is an equally wide variation in the
chemopreventive action of different retinoids
against carcinogen-induced bladder cancer. In
animal studies two agents appeared to be
efficacious but with minimal toxicity- HPR and 13
cis N ethyl retinamide. The latter retinoid is
unusual in not being teratogenic. Dr Moon was
only aware of one in vivo situation in which
retinoids enhanced tumour growth. That tumour
was unusual, however, in requiring hormonal
stimulation for it to grow at all.
J. Turton (London) discussed the role of animal
models in predicting toxicity of retinoids in
humans. Reversible remodelling of young rat bones,
with a reduction in the diameter of the medullary
cavity was seen after administration of many
retinoids, but not HPR. Skeletal problems have
rarely been reported in humans unless they have
had several years treatment with retinoids, although
calcification of ligaments has been noted. The
animal models were able to predict the cutaneous,
conjunctival and skeletal toxicity of 13 cis retinoic
acid and etretinate.
Following the start of the Carotene
intervention study in physicians in the United
States, it was interesting to hear from A. Kalache
(Oxford) of the case control study of ,B Carotene
consumption in Brazil. Large amounts of red palm
oil, which is very rich in # Carotene, are consumed
by an immigrant group in Salvador. The cancer
incidence in this group was no different from
controls. N. Wald (London) pointed out that other
dietary studies which have shown a lower incidence
of cancer in those with a high intake of Vitamin A
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could be observing simply the effect of increased
vegetable and decreased meat intake. He dismissed
retrospective studies of retinol blood levels in
cancer patients as demonstrating abnormalities
associated with the development of cancer. Four
prospective studies had shown low blood retinol
levels preceding the development of cancer
compared to those in subjects which remained
healthy but the difference was minimal in two of
these. The Oxford/BUPA study showed a reduction
in retinol levels only in those who developed cancer
within 2 years of the blood sample. This reduction
could be due to the cancer or could indicate the
short latency of some tumours. ,B Carotene levels,
however, were lower in cancer cases regardless of
length of follow up. In view of the tight control of
blood retinol levels it is debatable what relevance it
bears to tissue levels.
Chemoprevention trials in humans depend upon
defining a high risk group and deciding that the
risk of developing cancer outweighs the risk of
taking the chemopreventive agent. Patients with
recurrent superficial bladder cancers have at least a
50% chance of developing further benign bladder
cancers but also have an appreciably increased risk
of developing potentially fatal invasive bladder
cancer. Etretinate was shown by U. Studer (Berne)
and 0. Alfthan (Helsinki) to reduce the recurrence
rate of the superficial tumours in two randomized
trials. There was considerable controversy about
continuing such an agent for 5+ years to prevent
the invasive cancers and exposing 85%+ of patients
to unnecessary toxicity. If a currently running
Japanese study shows a beneficial effect of lower
non-toxic doses of etretinate on the superficial
tumours, a large intervention trial for both
superficial and invasive tumours will start in the
U.K. In view of the positive results of the
previously mentioned animal studies using HPR, a
large intervention study using this agent is also
planned in the U.K. Considering the encouraging
human data with etretinate it is to be hoped that
more centres will be able to demonstrate its effect
in their animal models. Otherwise there will be
doubts on the reliability of those models.
A defined high risk group where alternative
treatments do not already exist is difficult to find
for most cancers. The cervical dysplasias are one
group where topical retinyl acetate is being used by
F. Meyskens (Tucson). However, such therapy is
contentious due to the high spontaneous remission
rate of cervical dysplasias and the effective but
more aggressive alternative treatment that is
available. One also worries about the potential
teratogenic effects of retinoids in patients who
become pregnant. The animal studies suggest
human breast cancer as an ideal chemopreventive
model but J. Chamberlain (London) did not believe
that the increased risk of developing breast cancer
in any of the so far defined high risk groups was
sufficient to justify intervention. Nevertheless, a
randomized intervention study using HPR is
planned to start soon in Milan in over 4000 women
with breast cancer, to examine the incidence of
contralateral tumours.
It was considered that there were too few pre-
cancerous head and neck lesions, such as
leukaplakias, and that the 17% incidence of
metachranous tumours was spread over too long a
time period to justify chemoprevention trials using
retinoids.
W. Shui (Hong Kong) discussed the high
incidence of oesophageal carcinoma in China.
Oesophageal dysplasia which progresses to cancer
within 5 years in up to 20% of cases can be
detected by population screening using cytological
methods. Intervention studies using retinyl
palmitate are underway but no results are yet
available.
Ulcerative colitis, colonic dysplasia, polyposis coli
and abnormal mucin production were mentioned as
risk factors for development of colon cancer. Two
trials investigating retinoid chemoprevention of
cancer development in patients with polyposis coli
have begun in the United States. Two trials have
also begun in the United States looking at
bronchial mucosa metaplasia and dysplasia in
smokers receiving retinoids.
In vitro experiments suggest that some retinoids
might be useful in a therapeutic mode as well as in
chemo-prophylaxis. R. Lotan (Houston) reported
that retinoids induced growth inhibition in 60% of
over 100 different tumour cell cultures, and
stimulation of growth was only seen in a single
melanoma culture. E. Lasnitski (Cambridge) found
that retinoids could reverse carcinogen-induced
proliferation in organ cultures but were not
effective against established tumours. Most
transplantable animal tumours are resistant to the
effect of retinoids. However, S. Eccles (London)
found that retinoids could inhibit the growth of
several immunogenic transplantable tumours in
syngeneic animals but were ineffective against non-
immunogenic tumours, and that Cyclosporin A
immunosuppression abolished the effect of retinoids
on immunogenic tumours. Although some tumours
responded in vitro there was no correlation with
their in vivo response. These findings may be
explained by the findings of G. Dennert (San
Diego). He reported that retinoids induce NK cell
cytotoxicity probably by stimulating Interleukin 2
production. If the growth inhibitory effect of
retinoids in vivo is mediated through stimulation of
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retinoids can inhibit cell mediated and humoral
immunity must be taken into account. Since
chemical carcinogens tend to induce strongly
immunogenic tumours, the possibility that the
"anti-carcinogenic" effect of retinoids may be at
least partly due to immunopotentiation needs to be
explored by conducting such experiments in
immunodeprived or aged hosts.
Studies of retinoids in patients with advanced
cancer have, as in the animal studies, been generally
disappointing. G. Rustin (London) found only one
marginal response in 14 patients with advanced
melanoma and no evidence of etretinate inducing
differentiation in 8 patients with testicular
teratormas. F. Meyskens (Tucson) treated 20
melanoma patients with 13 cis retinoic acid and
found 2 partial and 1 mixed response. Vitamin A
and BCG have also been used in adjuvant studies
in patients with Stage I and II melanomas.
Although not yet significantly different, the survival
of Stage II patients appeared better in the Vitamin
A arm whilst the survival of Stage I patients was
worse in the Vitamin A arm. Two further adjuvant
studies using 13 cis retinoic acid in melanoma are
underway. A few responses have been seen in
patients with squamous cell carcinomas of the head,
neck and lung but of more interest was the report
that 4 out of 5 patients with choriocarcinoma
responded to 13 cis retinoic acid. This retinoid
appears to be one of the standard treatments for
mycosis fungoides with at least 50% of patients
having responses of their skin lesions. Retinoids
also have a definite place in the treatment of actinic
keratoses, keratoacanthomas and in the treatment
and prevention of recurrence of multiple basal cell
carcinomas.
Retinoids have been used in culture to induce
leukaemic cells to differentiate. Whilst T.R.
Breitman (Bethesda) could only induce
differentiation in cells from patients with acute
promyelocytic leukaemia, J. Francis (London) found
that differentiation occurred after retinoid addition
to cultures of cells from patients with most acute
leukaemias and myeloid dysplasias. The fact that
this differentiation can be enhanced by PGE2
monocyte-derived differentiation inducing activity
(DIA) and low dose cytosine arabinoside and
thioguanine has led to clinical trials of these
combinations. Here again the search continues for
the most active retinoid with the least toxicity.
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